Company News - VC and PE investment business - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 02 - 05

Beyond Nanshan's Trillion GDP: Longhua's First Shot on the 2026 STAR Market

IntroductionOn February 5, 2026, Insight Lifetech officially listed on the Sci-Tech Innovation Board (STAR Market).On January 30, 2026, the Nanshan District Statistics Bureau released the main economic indicators for Nanshan District for January–December 2025. According to the unified results of Shenzhen's Gross Domestic Product, Nanshan District's GDP for 2025 reached 1,010.238 billion RMB, representing a year-on-year growth of 6.3% at constant prices, capturing national attention.Under the dazzling spotlight on Nanshan, another dynamic area of Shenzhen—Longhua District—is quietly ris...

浏览次数：4

查看详情>>

发布时间: 2026 - 02 - 04

In Search of "China's Musk": A Historic Invitation

Part 01In Search of "The Musk" When Teslas cruise down the streets,When SpaceX rockets streak across the sky,We cannot help but ask ourselves:In China today,Who will become the "Musk" of the bio-economy?In recent years,China's biopharmaceutical industry has developed rapidly.The number of innovative drug pipelines currently in development is second only to the United States,Greater than the sum of Europe and Japan.In 2024, the number of new drug molecules discovered in China exceeded that of the US for the first time.According to statistics from the PharmCube NextP...

浏览次数：1

查看详情>>

发布时间: 2026 - 01 - 31

Monthly Health Digest | January 2026

Preface:In January, the "Spring Festival Gala" of the global biopharmaceutical industry – the 44th Annual J.P. Morgan Healthcare Conference – was held grandly in San Francisco, USA. Efung Capital's portfolio companies, including Ascentage Pharma, Hangzhou Gaoguang, Andao Pharma, Biao Xin Bio, and Mai Lian Ke, made major appearances, collectively showcasing the cutting-edge power of Chinese innovative drug companies.Efung's portfolio companies also achieved continuous breakthroughs in key areas such as clinical trials, regulatory approvals, and collaborations, outlining a clea...

浏览次数：1

查看详情>>

发布时间: 2026 - 01 - 19

HighLight Pharma Reports Positive Interim Phase III Results for CSU Drug TLL-018

January 18, 2026 – HighLight Pharmaceutical Co., Ltd. announced positive topline data from a pre-specified interim analysis of its Phase III clinical trial (NCT06396026, hereinafter referred to as "the study") evaluating TLL-018 (generic name: Jinoxitinib), an oral small-molecule JAK1/TYK2 inhibitor, for the treatment of Chronic Spontaneous Urticaria (CSU). The interim analysis showed that TLL-018 met the primary endpoint, demonstrating statistically significant superiority over placebo in both primary and multiple secondary efficacy endpoints, along with a favorable safety and ...

浏览次数：1

查看详情>>